开放获取期刊获得更多读者和引用
700 种期刊 和 15,000,000 名读者 每份期刊 获得 25,000 多名读者
Shuofeng Yuan
The COVID-19 pandemic is a serious problem of the new era. Acute respiratory distress syndrome (ARDS) and respiratory failure are the major lung diseases in COVID-19 patients. Although a COVID-19 vaccine is now available, there is still an urgent need to find potential treatments to reduce the impact of her COVID-19 on already sick patients. Several experimental drugs have been approved by the FDA, but their efficacy and possible side effects are unknown. An increasing number of studies worldwide investigating potential COVID-19-related therapies may help identify effective ARDS treatments. This review article first provides an overview of the immunopathology of ARDS. He then outlines the management of his COVID-19 patient requiring intensive care unit (ICU), focusing on current treatment strategies being evaluated in clinical trials for patients with COVID-19-induced ARDS.